Phase III study of S-1 plus intravenous and intraperitoneal paclitaxel versus S-1 plus cisplatin for gastric cancer with peritoneal metastasis
Phase of Trial: Phase III
Latest Information Update: 10 May 2018
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary) ; Paclitaxel (Primary) ; Cisplatin
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- Acronyms PHOENIX-GC
- 10 May 2018 Results published in the Journal of Clinical Oncology
- 07 Jan 2017 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 Primary endpoint (Overall survival) has not been met according to the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.